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The goal of vaccination to prevent tuberculosis disease (TB) is to oﬀer long-term protection to the individual and the community.
In addition, the success of any protective TB vaccine should include the ability to limit cavitary formation and disease progression.
The current BCG vaccine protects against disseminated TB disease in children by promoting development of antigenic-speciﬁc
responses. However, its eﬃcacy is limited in preventing postprimary pulmonary disease in adults that is responsible for the
majority of disease and transmission. This paper illustrates the use of lactoferrin as an adjuvant to boost eﬃcacy of the BCG
vaccine to control organism growth and limit severe manifestation of pulmonary disease. This resulting limitation in pathology
may ultimately, limit spread of bacilli and subsequent transmission of organisms between individuals. The current literature is
reviewed, and data is presented to support molecular mechanisms underlying lactoferrin’s utility as an adjuvant for the BCG
vaccine.
1.Introduction
Tuberculosis (TB) is responsible for approximately 1.8
million deaths each year and is the leading bacterial cause of
deathworldwide[1].Nearlyone-thirdoftheworldislatently
infected with Mycobacterium tuberculosis (MTB), making
eradicationofthisdiseaseextremelydiﬃcult.ThecurrentTB
vaccine is an attenuated strain of Mycobacterium bovis Bacil-
lus Calmette Guerin (BCG). BCG is eﬀective in protecting
against disseminated disease in children; however, its eﬃcacy
is limited in preventing pulmonary disease in adults [2–4].
While new vaccines are currently in development [5, 6],
BCG remains the only TB vaccine approved for human use.
Thus, one promising avenue is to develop adjuvants that are
capable of improving eﬃcacy of the existing BCG vaccine.
This paper reviews the activity of one particular adjuvant,
lactoferrin, focusing primarily on its immune modulatory
eﬀects and its potential to improve BCG eﬀectiveness in the
mouse model of TB infection.
2. Host Immune Responses against
MTB Infection
Vaccines represent one of the most powerful and cost-
eﬀective mechanisms for prevention of infectious disease,
with many successful eﬀorts leading to signiﬁcant reduction
in morbidity and mortality due to microbial assault [7].
The ultimate goal of vaccination to prevent TB disease
encompasses not only long-term protection to the individ-
ual, but also to the community [8, 9]. The transmissibility
of infection depends on its ability to escape from hosts that
demonstrate adequate immunity. A goal of a protective TB
vaccine should include the ability to limit cavity formation,
which is critical to subsequent spread of disease [10, 11].2 Tuberculosis Research and Treatment
Many scientists believe that the key to a successful TB vac-
cine includes generation of responses that limit deleterious
pathology in the lung. Alteration of the immunopathological
consequences of mycobacterial infection may lead to subse-
quent reduction in transmission of human disease.
The generation of a TH1i m m u n er e s p o n s ei sc r i t i c a l
for host control of mycobacteria [12]. Infection with MTB
begins with exponential growth of bacilli in macrophages.
A nascent granuloma forms as a result of the accumu-
lation of infected and noninfected macrophages respond-
ing to proinﬂammatory biomediators, likely triggered by
mycobacterial-derived glycolipid factors [13–17]. Dendritic
cell presentation of TB antigens, in the presence of cytokines
such as IL-12, initiates a CD4+ TH1i m m u n er e s p o n s e
[18]. IFN-γ production by TH1 cells activates macrophages,
resulting in phagosome acidiﬁcation and production of
both reactive oxygen and nitrogen species capable of killing
MTB [12]. CD4+ T-cells also assist in the development of
CD8+ cytotoxic T-cells, which are critical for control of
disease pathology [12]. The mechanisms underlying CD8+
stimulation towards generation of speciﬁc responses towards
MTB antigens are under active investigation. Finally, recent
studies suggest that TH17 cells, a relatively newly deﬁned T-
helper cell subset with modulatory functions, may also play
an important role in protection against MTB in vaccinated
animals [19]. Therefore, immunomodulatory agents used
as adjuvants to enhance eﬃcacy of the BCG vaccine are
expectedtoproducenotonlystrongTH1responses, butsolid
cytotoxic and regulatory responses as well.
MTB subverts immune recognition within macrophages
and limits phagosome-lysosome fusion events necessary for
destruction of organisms [21–23] and subsequent devel-
opment of adaptive responses [24, 25]. The BCG vaccine
generates host protective responses against MTB infection
by promoting development of a mycobacterial antigen-
speciﬁc delayed type hypersensitivity (DTH), speciﬁcally a
T-cell helper type-1 (TH1) immunity with antigen-speciﬁc
productionofinterferon-gamma(IFN-γ)[26].Inturn,these
T-cellresponsesactivatemacrophages,allowingcontainment
and control of organism growth. The strong TH1 immunity
isinpartcounterregulatedbyTH2elicited cytokines[27,28].
Thus, an eﬀective TB vaccine requires induction of strong
TH1 immunity, emphasizing the role of adjuvants that can
skew T-cell diﬀerentiation as an important component of
rationalvaccinedesign[28–30].Manyinvestigatorsspeculate
that use of deﬁned adjuvants to alter development of speciﬁc
memory T-cell subsets would function more eﬀectively over
longer periods to combat TB infection [31].
New evidence identiﬁed lactoferrin as a regulator of
immune responses to a variety of infectious and injurious
stimuli. Lactoferrin is a member of the transferrin family
a n di sf o u n di nm u c o s a ls e c r e t i o n sa sw e l la sn e u t r o p h i l
granules [32]. The neutrophilic glycoform of lactoferrin
plays a critical role in immune modulation [32]. Serum
lactoferrin concentration is normally low, at less than
1μg/mL, but increases considerably during inﬂammation
and injury [20, 33]. Receptors for lactoferrin are found on
many immune cells, including dendritic cells, macrophages,
and T-cells [34–36], contributing to the wide range of
reported immunomodulatory properties. These include
activation of macrophages, increasing polymorphonuclear
cell phagocytosis, promotion of B- and T-cell maturation,
and enhancement of antigen-speciﬁc immune responses
[37–39].
3. Lactoferrin Modulation of Innate Immunity
Lactoferrin has a number of eﬀects on innate antigen
presenting cells (APCs) that have the potential to modulate
T-cell responses. APCs, such as dendritic cells, present
antigen to naive CD4+ T-cells via major histocompatibility
complex II (MHC II) and costimulatory molecules such
as CD80, CD86, and CD40 [40, 41]. IL-12 production by
APCs promotes development of naive CD4+ T-cells to the
TH1 phenotype [42, 43]. Thus, modulation of APC surface
molecule expression and cytokine production may allow
enhancement of the protective immune response against
MTB infection.
Lactoferrin has the potential to enhance macrophage
and dendritic cell function as antigen presenters to activate
CD4+ T-cells. IFN-γ-stimulated macrophages infected with
mycobacteria, including BCG have decreased expression
of MHC II [44–46]. Addition of lactoferrin to activated
macrophages infected with BCG signiﬁcantly enhanced
MHC II expression [47, 48]. The CD86:CD80 ratio was
increased in macrophages and dendritic cells infected with
BCG and stimulated with lactoferrin [47, 49], suggesting
that lactoferrin-treated APCs are better able to promote
T-cellactivationduringantigenpresentationbyinfectedcells
[50, 51]. Indeed, BCG-infected macrophages and dendritic
cells cultured in the presence of lactoferrin signiﬁcantly
increased IFN-γ production from CD3+ and CD4+ cells
compared to APCs cultured without lactoferrin [47, 49].
Furthermore, lactoferrin enhanced expression of CD40 on
peritoneal macrophages and on the mouse macrophage
cell line RAW 264.7 [52]. Human immature dendritic cells
incubated with recombinant human lactoferrin increased
CD80, CD86, CD83, human leukocyte antigen II, as well
as chemokine receptors involved in migration to draining
lymph nodes [53].
As a proof of concept, we demonstrated that lactoferrin
could alter production of inﬂammatory cytokines from LPS
stimulated murine-derived or human-derived macrophages,
mimicking in part the status of infected cells. We ini-
tially reported that lactoferrin was eﬀective at augmenting
proinﬂammatory responses from stimulated splenocytes and
macrophages [54, 55]. For example, when whole splenocytes
isolated from C57BL/6 mice were stimulated with low levels
of LPS (100ng/mL), TNF-α, and IL-6 were modulated by
increasing concentrations of lactoferrin (1, 10μg/mL). In
addition, lactoferrin was able to directly stimulate TNF-α,
IL-6, and IL-12 production from J774A.1 and RAW 264.7
macrophages [54, 55]. A direct comparison of novel recom-
binant human neutrophilic lactoferrin [56] with milk-
derived lactoferrin was performed. The neutrophilic form
was able to induce high IL-12 production from the cultured
cells. For example, human THP-1 cells stimulated with LPS
incubated in the presence of increasing concentrations ofTuberculosis Research and Treatment 3
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Figure 1: Lactoferrin as a bridge between innate and adaptive immune function. Insult, deﬁned as infection or inﬂammatory stimulation,
leadstoactivationofthemonocyte/macrophagesystem(MØ),includingneutrophils(Nu).Inthecaseofprimaryvaccination,dendriticcells
(DCs) are also directly mediated. Activated neutrophils (Nu) degranulate at the site of inﬂammation and release lactoferrin. Depending on
the magnitude and/or duration of the insult, DCs mature to express diﬀerential amounts of speciﬁc cytokines that aﬀect local environments
to subsequently promote T-cell polarization into TH1, Treg,o rT H2 phenotypic populations (diagram adapted from [20]).
bovine lactoferrin, human milk-derived, or recombinant
human neutrophilic lactoferrin all signiﬁcantly diminished
TNF-α production in a dose-dependent manner. However,
only the human neutrophilic lactoferrin and the bovine-
derived lactoferrin were able to signiﬁcantly alter IL-6 and
IL-12p40 production. The milk lactoferrin isoform, which
contains fucose, was not able to do so. Nonfucosylated
moieties are characteristic of human neutrophilic leucocytes
whereas human milk-derived LF contains fucose residues
at the N-acetylglucosamine residue [57]. While others have
demonstrated that N-acetylneuraminic (sialic) acid as a
terminal sugar is important in propagation of other immune
responses, it was not a factor in modulation of activated
macrophages. Overall, the results for the recombinant
human lactoferrin were nearly identical to those obtained
using the bovine-derived lactoferrin.
IL-12 is an essential modulator of the TH1 cytokine
IFN-γ, both in the induction of TH1 cells from naive T-cells
and in maximizing IFN-γ production from diﬀerentiated
TH1e ﬀector and memory cells [58, 59]. Lactoferrin was
shown to function on leukocytes in vivo; intraperitoneal
injection of lactoferrin into mice increased IL-12 produc-
tion from recovered peritoneal macrophages [37]. Others
have demonstrated that oral administration of lactoferrin
increases IL-12p40 expression that is accompanied by a
decrease in IL-10 expression in the small intestines [60].
Indeed, in the presence of lactoferrin, macrophages infected
with BCG clearly demonstrated signiﬁcant increased ratio
of IL-12 relative to IL-10, a cytokine that negatively impacts
IL-12 [37]. Additionally, lactoferrin increased production of
TGF-β1 from BCG-infected dendritic cells and macrophages
[47, 49]. TGF-β1 in the presence of IL-6 has the potential
to promote the development of TH17 responses [61], which
have been shown to play an important role in the generation
of memory and recall responses to MTB antigens [19, 62].
Taken together, these studies indicate that lactoferrin is a
strong modulator of APC function. The eﬀect of lactoferrin
on innate cells involved in the initial encounter with
microbes gives it the potential to enhance the development
of acquired immunity, with clear molecular mechanisms to
further support its use as a vaccine adjuvant.
4. Lactoferrin Modulation of Adaptive
Immune Responses
Lactoferrin is a modulator capable of bridging innate and
adaptive immune functions (Figure 1). Soluble products
released during innate reactivity (whether due to infection,
immunization, or insult) serve to direct adaptive responses.
Lactoferrin also has the potential to limit insult-induced
oxidative stress while at the same time directing DCs to pro-
mote T-cell polarization [20, 32]. Receptors for lactoferrin
are found on CD4, CD8, and γδ T-cells [63]. Lactoferrin
also aﬀects the level of costimulatory surface molecules
that modulate T-cell activities, indicating that lactoferrin
may aﬀect T-cell activity and response to antigen. Human
lactoferrin promotes the maturation of double negative4 Tuberculosis Research and Treatment
mouse T-cells preferentially towards CD4 T-cells, possibly by
activating the MAP kinase pathway through Erk2 and p56lck
[64, 65]. Oral lactoferrin administration to mice increased
total circulating granulocytes as well as CD4 and γδ T-cells
[60]. Expression of leukocyte function associated antigen, an
adhesion molecule involved in cell-to-cell contact on both
CD4+ and CD8+ T-cells, was increased by lactoferrin [66].
Lactoferrin increased expression of the human T-cell ζ-chain
that is a component of the CD3 T-cell receptor complex
involved in signaling [67].
Lactoferrin promotes polarization of naive T-cells to
either TH1o rT H2 phenotypes depending on the antigen
and cytokine milieu. Classical studies demonstrated that
lactoferrin can promote the production of cytokines neces-
sary for the development of a TH1 response, with proven
enhancement of the DTH response to ovalbumin, sheep red
blood cells, and BCG [37, 68, 69]. The mechanisms appear
to be unique relative to eﬀects on mature T cells, where
diﬀerential activities with regard to eﬀector functions of T
cells with antigen speciﬁcity were found [70]. Transgenic
mice expressing human lactoferrin demonstrated increased
IFN-γ and TNF-α, accompanied by decreased IL-10 and IL-
5, during infection with Staphylococcus aureus [71]. Lacto-
ferrin administered orally increased TH1 T-cell responses,
measured by increased levels of IFN-γ, in naive and tumor-
harboring mice [72, 73]. Lactoferrin increased the IL-12:IL-
10 ratio in LPS stimulated splenocytes [74]. Additionally,
elimination of chronic hepatitis C virus is enhanced by
the addition of lactoferrin to interferon therapy, possibly
by enhancing TH1 responses [75]. Conversely, lactoferrin
decreased IFN-γ and increased IL-10 in an infection model
of Toxoplasma gondii, suggesting a promotion of a TH2
response [76]. The eﬀects of lactoferrin on the newly deﬁned
T-cell subset, TH17 cells, are currently unknown; however,
preliminary studies indicate that lactoferrin may promote
IL-17 responses to mycobacterial antigens (Hwang SA and
Welsh KJ, unpublished data).
Lactoferrin also modulates B-cell responses. Incubation
of immature B-cells with lactoferrin enhanced their ability
to promote proliferation of antigen-speciﬁc T-cells [39].
Additionally, lactoferrin promotes the maturation of mouse
immature B-cells as measured by increased expression of IgD
and the complement 3 receptor [39]. Lactoferrin demon-
strated an increase in the production of IgG and IgA from
Peyer’s patches in mice [77]. Antibodies in mice treated with
lactoferrin had increased levels of IgG in both the intestine
and serum [78]. Furthermore, lactoferrin overcomes the
suppressive eﬀects of cyclophosphamide and methotrexate
by increasing the number of antibody-forming cells and
humoral responses to sheep red blood cells [56, 79, 80].
These studies indicate that lactoferrin has direct eﬀects on
B-cells and potentially modulates their function as APCs to
promote T-cell responses.
5. Lactoferrin as Vaccine Adjuvant
Lactoferrin is an excellent candidate for a vaccine adjuvant
due to its eﬀects on APCs and modulation of the adaptive
immune response. Lactoferrin may speciﬁcally enhance the
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Figure 2: Reduced bacterial loads in BCG-immunized mice after
infectious challenge with MTB. C57BL/6 mice were immunized
with BCG (1 × 106 CFU/mouse; Pasteur strain TMC 1011, ATCC,
Manassas, VA) or BCG/bovine lactoferrin (10 or 100μg/mouse)
and boosted at 8 weeks. One group remained nonimmunized. At
12 weeks postboost, mice were aerosol infected with a low dose
(approximately 100 CFU/mouse) Erdman MTB (TMC 107, ATCC)
and monitored through day 65 postinfection for organ bacterial
load. All vaccinated mice were able to reduce bacterial load in tissue
following infectious challenge. Minimum number of animals per
group was 6 for controls and 10 for immunized mice. ∗P<. 05;
∗∗∗P<. 001.
eﬀectiveness of vaccines due to its proven enhancement of
the speciﬁc immune reactions to deﬁned antigens, including
BCG [37, 68, 69]. Most critical, lactoferrin has been shown
to protect against immune-mediated tissue damage [81, 82].
We hypothesize that the eﬀect of lactoferrin is directly
via host immune modulation, as it has been shown that
lactoferrin has no direct microbicidal activity on BCG,
whethergrowninbrothcultureorwhenaddedtomonocytes
already infected with organisms [47, 49].
Studies from our laboratory demonstrate that bovine
lactoferrin, as well as human lactoferrin, added to theTuberculosis Research and Treatment 5
Non-immunized
(a)
BCG
(b)
BCG/Lf 10μg
(c)
BCG/Lf 100μg
(d)
Figure 3: Protective histopathology following infectious challenge in lactoferrin adjuvant immunized mice. C57BL/6 mice were immunized
asdetailedinFigure 2withBCGorBCG/bovinelactoferrin(10or100μg/mouse)andaerosolchallenged12weeksafterﬁnalboost.Atday65
postchallenge, lungs were collected, formalin ﬁxed, and stained with hematoxylin and eosin (H&E). Comparison is made to nonimmunized,
infected controls. A mixed presence of lymphocytes and activated macrophages indicative of a protective response is identiﬁed in the
BCG alone vaccinated group. The addition of lactoferrin at either concentration resulted in a conﬁned granulomatous response with
focal lymphocytic accumulation and limited to no aggravated macrophage or polymorphonuclear insult. Images were visualized at 100x
magniﬁcation.
BCG vaccine led to better protection against challenge
with virulent organisms, indicated by decreased bacterial
burden in the lung and spleen, than BCG alone [55, 81,
83, 84]. Mice vaccinated with BCG/bovine lactoferrin had
increased lung expression of IFN-γ mRNA at early times
postchallenge with virulent MTB, suggesting enhanced TH1
responses at sites of clinical importance. Splenic recall
responses to heat-killed BCG in mice given the BCG/bovine
lactoferrin vaccine demonstrated increased levels of IFN-γ
and other proinﬂammatory mediators, compared to mice
vaccinated with only BCG. IL-4 was reduced in these groups
[81]. Lung histopathology was also signiﬁcantly reduced
in mice immunized with BCG/lactoferrin, demonstrating
focal, lymphocytic, granulomas surrounded by normal lung
parenchyma. The enhanced protective eﬀects of BCG/bovine
lactoferrin vaccine extend to BALB/c mice, which typically
demonstrate decreased TH1 responses to MTB compared to
C57BL/6 mice [84].
Recently completed experiments identiﬁed lactoferrin
to function as an adjuvant at lower doses than originally
reported [55, 83], thus making this a more attractive
adjuvant for clinical use. Speciﬁcally, C57BL/6 mice were
immunized with BCG or with BCG and bovine lactoferrin
at 10 or 100μg/mouse. Mice were boosted at 8 weeks. At
12 weeks postboost, mice were aerosol infected with MTB
strain Erdman (TMC 107, ATCC) and monitored through
day 65 postinfection. One group remained nonimmunized.
Generally, all mice immunized with BCG or BCG/lactoferrin
demonstrated a signiﬁcant decrease in lung, spleen, and
liver organ colony forming units (CFUs) compared to
the nonimmunized group. In liver, mice immunized with
BCG/lactoferrin (10μg) demonstrated slightly greater6 Tuberculosis Research and Treatment
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Figure 4: Quantitative analysis of histopathological protective
response due to lactoferrin vaccination. Quantitative assessment
of BCG immunization with or without lactoferrin (at 10 or
100μg/mouse) as described in Figure 2 revealed signiﬁcant reduc-
tion in lung occlusion following aerosol infection with virulent
mycobacteria at 65 days postchallenge. Quantitation of lung occlu-
sion percent was completed using Image J (NIH) by comparing
total section area with total area of granulomas. Number of animals
per group ranged from 6 controls to 10 in the vaccinated groups.
∗∗P<. 01; NS: no signiﬁcant diﬀerence between groups.
decrease in organ bacterial loads compared to the BCG only
and BCG/lactoferrin (100μg) groups (Figure 2). Previous
studies indicated that the 100μg dose of lactoferrin was able
to reduce organ bacterial loads at 4 weeks postchallenge
[55, 84], but this was evident at earlier times postchallenge
than reported here. The fact that lactoferrin may be used
at doses tenfold lower than previously reported conﬁrms its
ability to function as an immune mediator at low levels and
hasbeenreportedforitsuseinothermodelsofinﬂammation
[20, 33].
Histological analysis revealed that immunization with
BCG and lactoferrin at either dose resulted in similar
improvements in pathological development to infectious
challenge. The addition of lactoferrin to the vaccine led
to focal granulomas with tight lymphocytic clusters and
minimized inﬂammation in the surrounding parenchyma.
In contrast, the nonimmunized and BCG immunized groups
developed large granulomas with loosely clustered lympho-
cytes and activated foamy macrophages, along with manifes-
tations of inﬂammation in the surrounding tissue (Figure 3).
The BCG alone group demonstrated histological changes,
but they included the presence of activated macrophages,
which are assumed to contribute to the production of
deleterious and pathologically active mediators [85–88].
Quantitative analysis of the percentage of lung tissue occu-
pied by granuloma lesions reconﬁrmed the histological
ﬁndings (Figure 4). Mice vaccinated with BCG admixed
with 10 or 100μg/mouse of lactoferrin showed signiﬁcant
decreases in lung occlusion percent compared to both the
BCG only and nonimmunized groups. Of interest was the
observation that large pathological protection was apparent
in the absence of reduction in bacterial loads and that
this reduction in pathology was seen using lower levels of
lactoferrin. In all studies speciﬁc biomarkers reﬂected the
activity of a disease process (bacterial loads, granuloma for-
mation, or production of cytokines). While these indicators
should theoretically correlate (either directly or inversely)
with disease progression, in practice many biomarkers are
likely dependent upon elaborate mechanisms. As lacto-
ferrin is a multifunctional protein, it activates multiple
pathways with diﬀerential modiﬁcations to speciﬁc disease
processes.
While the bovine form of lactoferrin added to the BCG
vaccine enhanced the eﬀectiveness of BCG vaccination, it
is unlikely that bovine lactoferrin can be used parenterally
in humans due to the possibility of inducing allergic
responses. Human recombinant lactoferrin that has identical
glycosylationpatternstoneutrophiliclactoferrinwasrecently
developed using a Pichia pastoris expression system [56].
The sialylated and nonsialylated variants of human lacto-
ferrin were admixed into the BCG vaccine and examined
for their ability to provide enhanced protection following
challenge with virulent MTB [81]. The sialylated form of
recombinant human lactoferrin added to the BCG vaccine
enhanced protection, as indicated by decreased bacterial
load in the lung, spleen, and liver. Antigen-speciﬁc recall
responses to heat-killed BCG demonstrated increased IFN-γ
by splenocytes of the mice vaccinated with sialylated human
lactoferrinasanadjuvant.Lunginﬂammatorypathologywas
also signiﬁcantly reduced by the addition of recombinant
human lactoferrin.
The reduction of lung pathology by addition of lacto-
ferrin to the BCG vaccine has a number of signiﬁcant
implications. Destruction of lung tissue likely contributes
to the transmission of MTB and is an important cause of
morbidity [89]. Indeed, a strategy for rational vaccine design
includes mechanisms that reduce immunopathology and
disseminationofinfectionatlatertimepoints[8,9].Vaccines
thatreducepathologyafterchallengewithvirulentMTBmay
also correlate with disease protection [31].
6. Summary
Our underlying hypothesis for utilizing lactoferrin to boost
eﬃcacy of the BCG vaccine is in agreement with assessment
that prolonged survival may be predicated on changes in the
pathological manifestation of disease within lung tissue [90],
with improvement seen in the absence of decreased bacillary
load. Indeed, limiting pathology would create a “ﬁrebreak”
to slow transmission, even in spite of organisms remaining
hidden in various organs [91]. Evidence to support this
is found in the guinea pig model, suggesting that survival
following challenge may occur in vaccinated animals in
the absence of decreased early bacillary loads [11, 92, 93].
The data presented in this paper indicates that lactoferrin
given at 10μg/mouse can function with resultant protective
pathology while retaining full adjuvant activity [56, 81, 83].
The ability to lower the dose of lactoferrin while maintaining
activity is necessary for clinical utility of lactoferrin as an
adjuvant to boost BCG vaccine in humans.
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